Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Canada
Disease-Free Survival
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma
Neoplasm Recurrence, Local
Spain
Treatment Outcome
United States

authors with profiles

Andrzej Jakubowiak